Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
The purpose of this study is to evaluate the efficacy of darbepoetin alfa versus placebo in reducing the occurrences of red blood cell transfusions in subjects with anemia of cancer who are not receiving chemotherapy.
Anemia|Cancer
DRUG: Darbepoetin Alfa|DRUG: Placebo
Occurrences of red blood cell transfusion, from study day 29 (week 5) to week 17
Incidence of first red blood cell transfusion, from week 5 (study day 29) to week 17 (study day 119)|Change in hemoglobin concentration measured, from baseline (study day 1) to EOTP|Adverse events and serious adverse events, throughout study for subjects who received at least 1 dose of investigational product|Survival, deaths on study and deaths in long-term follow-up period for subjects who received at least 1 dose of investigational product|Incidence, if any, of neutralizing antibody formation to investigational product, throughout study for subjects who received at least 1 dose of investigational product
The purpose of this study is to evaluate the efficacy of darbepoetin alfa versus placebo in reducing the occurrences of red blood cell transfusions in subjects with anemia of cancer who are not receiving chemotherapy.